Table 1.
General description of study population
| N = 161 | |
|---|---|
| Age in years, median (IQR) | 49 (44–53) |
| Male sex, n (%) | 126 (78.3) |
| Years since HIV diagnosis, median (IQR) | 17 (10–23) |
| CD4 nadir, median (IQR) | 170 (73–290) |
| History of AIDS, n (%) | 47 (29.3) |
| N° previous ART combinations, median (IQR) | 5 (3–7) |
| Years on ART, median (IQR) | 14 (6–18) |
| Previous ART that included, n (%): | |
| NRTI | 95 (59) |
| NNRTI | 91 (56.5) |
| PI | 128 (79.5) |
| II | 16 (9.9) |
| ART strategy, n(%): | |
| Triple therapy | 92 (57.1) |
| Dual therapy | 53 (32.9) |
| Monotherapy | 16 (9.9) |
| Baseline VL (bVL): | |
| < 50 copies/mL, n (%) | 120 (74.5) |
| 50–1000 copies/mL, n (%) | 41 (25.5) |
| Baseline CD4 count, median (IQR) | 618 (370–861) |
IQR: interquartile range; ART: antiretroviral therapy; NRTI: nucleoside analog reversetranscriptase inhibitors; NNRTI: non-nucleoside analog reverse-transcriptase inhibitors; PI: protease inhibitors; II: integrase inhibitors; VL: viral load